Genentech Biooncology
Genentech Biooncology
    • Home 

    • Research Education 

    • Research VEGF 

    • The role of VEGF across tumor types 

    • VEGF in gastric cancer 

    • GLOSSARY
    • ON
    • OFF
  • Print
  • share
 
 
' The related resources bookmark allows you to jump directly to other pages on the site that contain information directly related to the topics you're currently exploring.
  • Home Page
  • What's New?
  • Tumor Types
  • Molecular Causes of Cancer
  • Biological Pathways
  • Therapeutic Targets
  • Pipeline Molecules
  • Research Education
    • Research ADCs
    • Research Apoptosis
    • Research B cell
    • Research BRAF
    • Research Cancer Immunotherapy
    • Research HDIs
    • Research HER Pathways
    • Research MET
    • Research VEGF
      • Why is the VEGF ligand essential throughout tumor development?
      • What are the strategies for inhibiting the VEGF pathway?
      • What are the effects of direct VEGF ligand inhibition?
      • Why is continued VEGF inhibition important?
      • Why do tumors progress?
      • The role of VEGF across tumor types
        • VEGF in lung cancer
        • VEGF in colorectal cancer
        • VEGF in renal cell carcinoma
        • VEGF in glioblastoma
        • VEGF in ovarian cancer
        • VEGF in bladder cancer
        • VEGF in gastric cancer
          • VEGF expression in gastric cancer
          • Regulation of VEGF expression
          • Serum VEGF as a clinical marker
          • VEGF and tumor progression in gastric cancer
          • VEGF, MVD, and metastases in gastric carcinoma
          • Summary
        • VEGF in multiple myeloma
        • VEGF in pancreatic cancer
      • Slide decks and videos
      • Glossary
  • Clinical Trials
  • Resources
  • Contact Us
Register for Updates Unsubscribe Share
Register for Updates Unsubscribe Share

Related Resources for this page:

  • Tumor Types
    • Colorectal Cancer
    • Glioblastoma
    • Lung Cancer
    • Ovarian Cancer
    • Pancreatic Cancer
    • Renal Cell Carcinoma
  • Molecular Causes of Cancer
    • Evading growth suppressors
    • Inducing angiogenesis
    • Activating invasion and metastasis
  • Biological Pathways
    • Angiogenic Signaling
    • Apoptosis
    • B-cell Surface Proteins
    • HER Signaling
    • MAPK Signaling
    • PI3K/Akt/mTOR Signaling
  • Therapeutic Targets
    • Bcl-2
    • HER1
    • HER2
    • HER3
    • HER4
    • VEGF
  • Clinical Trials
    • Gastric Cancer
  • Cancer Biomarkers
    • Gastric Cancer
      • Receptor-Mediated Endocytosis
      • Cytotoxic agent
      • What are ADCs?
      • Stable linker
      • Monoclonal antibody
      • Current research in ADCs
      • Targeting cancers with ADCs
      • Glossary
      • A brief history of ADCs
      • How are ADCs designed to work?
      • Research ADCs
      • Multimedia Resources
  • Future Directions
    • Antibody-Drug conjugates
      • HER Signaling
      • Receptor-Mediated Endocytosis
      • Anti-PDL1 (MPDL3280A)
      • Cytotoxic agent
      • What are ADCs?
      • Stable linker
      • Monoclonal antibody
      • Current research in ADCs
      • Targeting cancers with ADCs
      • Glossary
      • A brief history of ADCs
      • How are ADCs designed to work?
      • Research ADCs
      • Multimedia Resources
    • Glycoengineered Antibodies
      • HER Signaling
    • Non-Antibody Biologics
      • Apoptosis
    • Targeted Small Molecules
      • Apoptosis
      • MAPK Signaling
      • PI3K/Akt/mTOR Signaling
      • Glossary
      • Gastric Cancer
    • Traditional Monoclonal Antibodies
      • Angiogenic Signaling
      • B-cell Surface Proteins
      • HER Signaling
      • Anti-PDL1 (MPDL3280A)
      • Gastric Cancer

Video

Full VEGF & angiogenesis

View video now

Links

  • VEGF in NSCLC
  • VEGF in CRC
  • VEGF in RCC
  • VEGF in GBM
  • VEGF in ovarian cancer
  • VEGF in bladder cancer
  • VEGF in multiple myeloma
  • VEGF in pancreatic cancer
Share

VEGF and angiogenesis in gastric cancer

...VEGF and the angiogenesis promoted by VEGF play important roles in cancer growth, infiltration and metastasis in gastric carcinoma.

— Kösem M, Tuncer I, Kotan Ç, et al. Hepato-Gastroenterology. 20091

Vascular endothelial growth factor (VEGF) is one of the most potent angiogenic factors discovered to date. It is a signaling molecule secreted by many solid tumors.2,3 High VEGF expression is seen in many human cancer cells, and is also expressed in stromal cells, particularly at sites of relative hypoxia.3-5 VEGF promotes endothelial cell proliferation and migration, and induces angiogenesis.6,7 As its other name—vascular permeability factor (an earlier term for the protein)—suggests, VEGF increases vascular permeability to plasma and its proteins, a characteristic of tumor microvasculature.3

Gastric cancers are overwhelmingly sporadic malignancies, developing in people without a high-risk germ-line mutation.8,9 Adenocarcinomas predominate in the stomach in more than 95% of malignancies. The majority of these express VEGF as an angiogenic factor that results in neovascularization within carcinomas. According to the Lauren classification, these neoplasms are described as intestinal or diffuse types. Intestinal tumors are glandular in nature, while the less common diffuse tumors lack cohesion and functionality.9

Gastric cancer was ranked as the fourth most common global malignancy in 2008, with an estimated 989,600 new cases. About 738,000 people worldwide died from gastric cancer in 2008.10 Gastric carcinoma grows aggressively and, following total gastrectomy, the cancer recurs in nearly 30% of patients.11 Among patients with advanced gastric carcinoma, only 30% are expected to survive 5 or more years after curative resection.12

This section highlights VEGF expression in gastric cancer, as well as the role of VEGF in gastric tumor progression, increased microvessel density (MVD), and malignant metastases.

For more information on a specific topic regarding VEGF and angiogenesis in gastric cancer, click on the links below.

In This Section

  • VEGF expression in gastric cancer
    • Regulation of VEGF expression
    • Serum VEGF as a clinical marker
  • VEGF and tumor progression in gastric cancer
    • VEGF, MVD, and metastases in gastric carcinoma
  • Summary: VEGF and gastric cancer
References:
1.
Kösem M, Tuncer I, Kotan Ç, et al. Hepatogastroenterology. 2009;56:1236-1240. PMID: 19760978
2.
Suzuki S, Dobashi Y, Hatakeyama Y, et al. BMC Cancer. 2010;10:659. PMID: 21118571
3.
Nagy JA, Feng D, Vasile E, et al. Lab Invest. 2006;86:767-780. PMID: 16732297
4.
Murat A, Migliavacca E, Hussain SF, et al. PLoS One. 2009;4:e5947. PMID: 19536297
5.
Pinto MP, Badtke MM, Dudevoir ML, et al. Cancer Res. 2010;70:2655-2664. PMID: 20332242
6.
Zhao HC, Qin R, Chen XX, et al. World J Gastroenterol. 2006;12:7598-7603. PMID: 17171787
7.
Wang S, Li X, Parra M, et al. Proc Natl Acad Sci U S A. 2008;105:7738-7743. PMID: 18509061
8.
National Cancer Institute dictionary of genetics terms: http://www.cancer.gov/geneticsdictionary?expand=All. Accessed May 16, 2011.
9.
Smith MG, Hold GL, Tahara E, et al. World J Gastroenterol. 2006;12:2979-2990. PMID: 16718776
10.
American Cancer Society. Global cancer facts & figures, 2nd edition, 2011. http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/
documents/document/acspc-027766.pdf
. Accessed July 15, 2011.
11.
Maeda K, Chung YS, Ogawa Y, et al. Cancer. 1996;77:858-863. PMID: 8608475
12.
Tanigawa N, Amaya H, Matsumura M, et al. Cancer Res. 1996;56:2671-2676. PMID: 8653715
 
  • SITEMAP
  • /
  • PRIVACY POLICY
  • /
  • TERMS & CONDITIONS
  • /
  • CONTACT US
  • /
  • © 2013 Genentech USA, Inc. All rights reserved.
  • /
  • BIO0000907901
Next section: VEGF expression in gastric cancer »

© 2011 Genentech USA, Inc. All rights reserved